|
Gene: STOM |
Gene summary for STOM |
Gene summary. |
Gene information | Species | Human | Gene symbol | STOM | Gene ID | 2040 |
Gene name | stomatin | |
Gene Alias | BND7 | |
Cytomap | 9q33.2 | |
Gene Type | protein-coding | GO ID | GO:0002028 | UniProtAcc | F8VSL7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2040 | STOM | LZE4T | Human | Esophagus | ESCC | 1.97e-14 | 7.94e-01 | 0.0811 |
2040 | STOM | LZE5T | Human | Esophagus | ESCC | 2.18e-04 | 1.82e-01 | 0.0514 |
2040 | STOM | LZE7T | Human | Esophagus | ESCC | 1.44e-07 | -1.96e-01 | 0.0667 |
2040 | STOM | LZE20T | Human | Esophagus | ESCC | 1.04e-09 | 8.52e-01 | 0.0662 |
2040 | STOM | LZE21D1 | Human | Esophagus | HGIN | 6.35e-04 | -2.51e-01 | 0.0632 |
2040 | STOM | LZE24D1 | Human | Esophagus | HGIN | 7.12e-08 | 3.34e-01 | 0.054 |
2040 | STOM | LZE24T | Human | Esophagus | ESCC | 2.51e-14 | 9.76e-01 | 0.0596 |
2040 | STOM | P2T-E | Human | Esophagus | ESCC | 1.46e-07 | 3.13e-01 | 0.1177 |
2040 | STOM | P4T-E | Human | Esophagus | ESCC | 9.71e-14 | 3.77e-01 | 0.1323 |
2040 | STOM | P5T-E | Human | Esophagus | ESCC | 1.40e-20 | 6.42e-01 | 0.1327 |
2040 | STOM | P9T-E | Human | Esophagus | ESCC | 9.62e-12 | 6.69e-01 | 0.1131 |
2040 | STOM | P10T-E | Human | Esophagus | ESCC | 2.46e-07 | -4.44e-01 | 0.116 |
2040 | STOM | P11T-E | Human | Esophagus | ESCC | 4.60e-06 | 6.64e-01 | 0.1426 |
2040 | STOM | P12T-E | Human | Esophagus | ESCC | 1.18e-47 | 1.55e+00 | 0.1122 |
2040 | STOM | P15T-E | Human | Esophagus | ESCC | 3.20e-37 | 1.26e+00 | 0.1149 |
2040 | STOM | P16T-E | Human | Esophagus | ESCC | 7.80e-16 | -2.68e-01 | 0.1153 |
2040 | STOM | P17T-E | Human | Esophagus | ESCC | 5.67e-03 | 6.19e-01 | 0.1278 |
2040 | STOM | P19T-E | Human | Esophagus | ESCC | 4.81e-03 | 1.23e+00 | 0.1662 |
2040 | STOM | P20T-E | Human | Esophagus | ESCC | 1.68e-16 | 7.22e-01 | 0.1124 |
2040 | STOM | P21T-E | Human | Esophagus | ESCC | 1.46e-28 | 1.06e+00 | 0.1617 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001905818 | Prostate | BPH | viral life cycle | 112/3107 | 317/18723 | 2.87e-16 | 5.54e-14 | 112 |
GO:190382918 | Prostate | BPH | positive regulation of cellular protein localization | 98/3107 | 276/18723 | 1.46e-14 | 1.84e-12 | 98 |
GO:000660518 | Prostate | BPH | protein targeting | 102/3107 | 314/18723 | 2.51e-12 | 2.05e-10 | 102 |
GO:003238610 | Prostate | BPH | regulation of intracellular transport | 106/3107 | 337/18723 | 8.77e-12 | 6.70e-10 | 106 |
GO:190495117 | Prostate | BPH | positive regulation of establishment of protein localization | 101/3107 | 319/18723 | 1.77e-11 | 1.24e-09 | 101 |
GO:003315716 | Prostate | BPH | regulation of intracellular protein transport | 76/3107 | 229/18723 | 5.05e-10 | 2.56e-08 | 76 |
GO:005122217 | Prostate | BPH | positive regulation of protein transport | 93/3107 | 303/18723 | 6.94e-10 | 3.25e-08 | 93 |
GO:004440318 | Prostate | BPH | biological process involved in symbiotic interaction | 90/3107 | 290/18723 | 6.98e-10 | 3.25e-08 | 90 |
GO:000915018 | Prostate | BPH | purine ribonucleotide metabolic process | 107/3107 | 368/18723 | 1.18e-09 | 5.19e-08 | 107 |
GO:003238816 | Prostate | BPH | positive regulation of intracellular transport | 68/3107 | 202/18723 | 2.08e-09 | 8.35e-08 | 68 |
GO:000914417 | Prostate | BPH | purine nucleoside triphosphate metabolic process | 38/3107 | 88/18723 | 3.68e-09 | 1.41e-07 | 38 |
GO:000920510 | Prostate | BPH | purine ribonucleoside triphosphate metabolic process | 36/3107 | 82/18723 | 5.49e-09 | 1.99e-07 | 36 |
GO:000683916 | Prostate | BPH | mitochondrial transport | 79/3107 | 254/18723 | 6.77e-09 | 2.38e-07 | 79 |
GO:000925917 | Prostate | BPH | ribonucleotide metabolic process | 108/3107 | 385/18723 | 8.73e-09 | 2.97e-07 | 108 |
GO:000616318 | Prostate | BPH | purine nucleotide metabolic process | 109/3107 | 396/18723 | 2.28e-08 | 6.94e-07 | 109 |
GO:001969317 | Prostate | BPH | ribose phosphate metabolic process | 109/3107 | 396/18723 | 2.28e-08 | 6.94e-07 | 109 |
GO:007252118 | Prostate | BPH | purine-containing compound metabolic process | 113/3107 | 416/18723 | 2.77e-08 | 8.13e-07 | 113 |
GO:00903169 | Prostate | BPH | positive regulation of intracellular protein transport | 55/3107 | 160/18723 | 3.09e-08 | 8.91e-07 | 55 |
GO:000914510 | Prostate | BPH | purine nucleoside triphosphate biosynthetic process | 31/3107 | 69/18723 | 3.22e-08 | 9.18e-07 | 31 |
GO:001598510 | Prostate | BPH | energy coupled proton transport, down electrochemical gradient | 17/3107 | 26/18723 | 3.61e-08 | 1.01e-06 | 17 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STOM | SNV | Missense_Mutation | c.863N>C | p.Gly288Ala | p.G288A | P27105 | protein_coding | tolerated(0.18) | benign(0) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
STOM | SNV | Missense_Mutation | novel | c.545N>T | p.Thr182Ile | p.T182I | P27105 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STOM | SNV | Missense_Mutation | rs747153047 | c.295N>G | p.Ile99Val | p.I99V | P27105 | protein_coding | tolerated(1) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STOM | SNV | Missense_Mutation | novel | c.428N>A | p.Thr143Asn | p.T143N | P27105 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-IR-A3L7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
STOM | SNV | Missense_Mutation | c.431N>A | p.Arg144His | p.R144H | P27105 | protein_coding | tolerated(0.09) | benign(0.168) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
STOM | SNV | Missense_Mutation | rs763192503 | c.572N>A | p.Arg191His | p.R191H | P27105 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-NH-A50T-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
STOM | SNV | Missense_Mutation | rs201671242 | c.673N>A | p.Glu225Lys | p.E225K | P27105 | protein_coding | deleterious(0.02) | possibly_damaging(0.617) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
STOM | SNV | Missense_Mutation | rs867557202 | c.299N>T | p.Ser100Leu | p.S100L | P27105 | protein_coding | deleterious(0) | possibly_damaging(0.672) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
STOM | SNV | Missense_Mutation | novel | c.857N>G | p.His286Arg | p.H286R | P27105 | protein_coding | tolerated(0.17) | benign(0.003) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
STOM | SNV | Missense_Mutation | novel | c.752N>A | p.Arg251Gln | p.R251Q | P27105 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |